COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report

Clinical and CT imaging features of 2019 novel coronavirus disease (COVID-19)

(2020) Ying Zhu et al.   JOURNAL OF INFECTION

COVID-19 Autopsies, Oklahoma, USA

(2020) Lisa M Barton et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study

(2020) Lennard Y W Lee et al.   LANCET

Moving towards personalized treatments of immune-related adverse events

(2020) Khashayar Esfahani et al.   Nature Reviews Clinical Oncology

CO-RADS – A categorical CT assessment scheme for patients with suspected COVID-19: definition and evaluation

(2020) Mathias Prokop et al.   RADIOLOGY

Patients with cancer appear more vulnerable to SARS-COV-2: a multi-center study during the COVID-19 outbreak

(2020) Mengyuan Dai et al.   Cancer Discovery

Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers

(2020) Jia Luo et al.   Cancer Discovery

Conducting Phase I Trials During the SARS-Coronavirus-2 Outbreak: About Science and Care

(2020) Angelo Dipasquale et al.   Frontiers in Oncology

Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks

(2020) Salvatore Crisafulli et al.   BIODRUGS

COVID-19 pneumonia and immune-related pneumonitis: critical issues on differential diagnosis, potential interactions, and management

(2020) Marco Russano et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Determinants of COVID-19 disease severity in patients with cancer

(2020) Elizabeth V. Robilotti et al.   NATURE MEDICINE

A decade of immune-checkpoint inhibitors in cancer therapy

(2020) Caroline Robert   Nature Communications

On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19

(2020) Thilo Gambichler et al.   Journal for ImmunoTherapy of Cancer

Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features

(2019) Michele Porcu et al.   Cancers

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

(2019) Filipe Martins et al.   Nature Reviews Clinical Oncology

Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features

(2019) Jonathan D. Schoenfeld et al.   Journal for ImmunoTherapy of Cancer

Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors

(2019) Fausto Petrelli et al.   JOURNAL OF IMMUNOTHERAPY

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

(2018) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease

(2018) Osamu Kanai et al.   Thoracic Cancer

Pneumonitis in Non-Small Cell Lung Cancer patients receiving Immune Checkpoint Immunotherapy: incidence and risk factors

(2018) Karthik Suresh et al.   Journal of Thoracic Oncology

Pneumonitis in Irradiated Lungs After Nivolumab

(2017) Farkhad Manapov et al.   JOURNAL OF IMMUNOTHERAPY

Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer

(2016) Mizuki Nishino et al.   JAMA Oncology

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology